Clinical trial NCT02291757: Efficacy and Safety of NEM® Brand Eggshell Membrane in Patients With Grade 2/3 Knee Osteoarthritis
Official title: Evaluation of the Efficacy and Safety of NEM® Brand Eggshell Membrane in Patients With Grade 2/3 Knee Osteoarthritis: A Multi-center, Randomized, Double-blind, Placebo-controlled, Single-crossover Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis, Knee
Lead sponsor: Generica Pharmaceuticals
Sponsor class: INDUSTRY
Collaborators: name: Optimum Contract Research Organisation
First posted: 2014-11-14
Enrollment: 166
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Single-crossover at 4 weeks
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study was designed to evaluate the efficacy and safety of NEM® brand eggshell membrane in patients with grades 2 and 3 knee osteoarthritis (OA) having significant joint pain and stiffness, in a large, multi-center clinical trial.

Detailed description: This study was designed to evaluate the efficacy and safety of NEM® brand eggshell membrane in patients with grades 2 and 3 knee osteoarthritis (OA) having significant joint pain and stiffness, in a large, multi-center clinical trial. Improvement in joint pain and stiffness, if any, will be evaluated using the Western Ontario and McMaster Universities osteoarthritis index ((WOMAC; v LK3.1: Turkish language translation). Improvement in knee range of motion (ROM), if any, will be measured by goniometer.

Eligibility criteria: Inclusion Criteria:

1. Subjects must be 40 years of age or older.
2. Subjects must be applied to the Physical Treatment and Rehabilitation clinics with knee pain complaints and the subjects must be diagnosed as knee osteoarthritis exactly with routine laboratory and X-RAY degeneration detection methods. Subjects must have 2nd or 3rd grade knee osteoarthritis diagnose according to the Kellgren Lawrance criteria as a result of the knee graph determined with Anteroposterior (AP) graph method while standing on referencing American College of Rheumatology (ACR) or The European Leauge Aganist Rheumatism (EULAR) 2010.
3. Male or female subjects can be included in the study.
4. Subject must not have been diagnosed with a joint or connective tissue (JCT) disease other than osteoarthritis (i.e. rheumatoid arthritis, gout, pseudo gout, paget.) by a licensed physician prior to enrollment evaluation.
5. Subject must have mild to moderate persistent joint pain lasting for at least 3 months with a score of at least 15 mm on a Patient's Assessment of Joint pain - WOMAC Osteoarthitiris Index and Visual Analog Scale (VAS).
6. Subjects must have disease complaints for at least 1-5 years.
7. Subject must diagnosed with 2nd or 3rd grade knee osteoarthritis according to Kellgren Lawrance criteria.
8. Body mess index of the subjects must be 35 or below.
9. Subject must be available for and willing to attend all evaluation visits.
10. Subject must be able and willing to give informed consent.
11. Subject must be willing to take NEM® or placebo and to stop taking all prescription medications, over-the-counter (OTC) treatments, or dietary supplements that might be considered analgesic or anti-inflammatory (i.e. Non Steroidal Anti Imflammatory Drugs - NSAIDs) or that might confound the study results, as judged by the clinical investigator. Examples of these types of medications are: aspirin (excluding 300 mg and over),paracetamol, ibuprofen, naproxen, oxycodone, propoxyphene, diclofenac, celecoxib, glucosamine, chondroitin, MSM (Methyl Sulfonylmethane) , white willow bark, turmeric or curcumin, Boswellia, etc.

    a. Washout Periods: Subjects are eligible to participate in the study following a 7-day washout period for narcotics, a 14-day washout period for analgesics \& NSAIDs, and a 90-day washout period for steroids or JCT dietary supplements (i.e. glucosamine, chondroitin, MSM, etc.)
12. Subjects must be willing to use only paracetamol as rescue pain medication, provided as part of the study.

Exclusion Criteria:

1. Subject has Grade IV (4) osteoarthritis (Kellgren-Lawrence) as judged by the clinical investigator
2. Subject is currently receiving therapy with remission-inducing drugs (i.e. methotrexate, Tumor Necrosis Factor (TNF) alpha blockers, steroids and glucosamine condtroitin) or any investigational drug.
3. Subject has been diagnosed with any confounding inflammatory disease or condition that would interfere with the assessment of the study treatment, as judged by the clinical investigator (i.e. pseudo gout, Paget's disease, chronic pain syndrome etc.).
4. Subject has been enrolled in a study to evaluate a JCT treatment in the past 6 months.
5. Subject has known allergy to eggs or egg products. If any subject becomes sensitive during the study, they will immediately be excluded from continuing in the study.

   a. Such sensitivity may be realized as a reaction to inoculations wherein the inoculate is derived from or contains egg components (i.e., influenza vaccine).
6. Subject body mess index greater than 35.
7. Pregnant and breastfeeding women.
8. Subject has severe persistent joint pain lasting for at least 3 months with a score of 80 mm or more on a Patient's Assessment of Joint pain WOMAC OA Index and Visual Analog Scale (VAS).
9. Subject is unwilling to forgo use of prescription, over-the-counter (OTC) treatments, and/or dietary supplements for the duration of the study.
10. Subject is involved in any other research study involving an investigational product (drug, device or biologic) or a new application of an approved product, within 30 days of screening.

Primary outcomes:
measure: Change in Total WOMAC Score from Baseline
timeFrame: 30 days
Secondary outcomes:
measure: Change in Range of Motion (ROM) from Baseline as measured by goniometer
timeFrame: 30 days
measure: Safety Evaluations as measured by number of Participants with Adverse Event
timeFrame: 90 days
Other outcomes:
Locations:
city: Antalya
country: Turkey
facility: Akdeniz University School of Medicine
city: Aydın
country: Turkey
facility: Adnan Menderes University School of Medicine
city: Bursa
country: Turkey
facility: Uludağ University School of Medicine
city: Erzurum
country: Turkey
facility: Atatürk University School of Medicine
city: İstanbul
country: Turkey
facility: İstanbul University Cerrahpaşa School of Medicine
city: İstanbul
country: Turkey
facility: İstanbul University İstanbul School of Medicine
city: İstanbul
country: Turkey
facility: Marmara University School of Medicine
city: Ordu
country: Turkey
facility: Ordu University School of Medicine
Study officials:
affiliation: Generica Pharmaceuticals
name: Meltem Çakmakgil, Dr.
role: STUDY_DIRECTOR
References: